000147216 001__ 147216
000147216 005__ 20240229123021.0
000147216 0247_ $$2doi$$a10.1038/s41409-019-0703-1
000147216 0247_ $$2pmid$$apmid:31558788
000147216 0247_ $$2ISSN$$a0268-3369
000147216 0247_ $$2ISSN$$a0951-3078
000147216 0247_ $$2ISSN$$a1476-5365
000147216 0247_ $$2altmetric$$aaltmetric:67524091
000147216 037__ $$aDKFZ-2019-02342
000147216 041__ $$aeng
000147216 082__ $$a610
000147216 1001_ $$aLuft, Thomas$$b0
000147216 245__ $$aEASIX and mortality after allogeneic stem cell transplantation.
000147216 260__ $$aLondon$$bNature Publishing Group55086$$c2020
000147216 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2019-09-26
000147216 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2020-03-01
000147216 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2020-03-01
000147216 3367_ $$2DRIVER$$aarticle
000147216 3367_ $$2DataCite$$aOutput Types/Journal article
000147216 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1586872335_14355
000147216 3367_ $$2BibTeX$$aARTICLE
000147216 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147216 3367_ $$00$$2EndNote$$aJournal Article
000147216 500__ $$a2020 Mar;55(3):553-561
000147216 520__ $$aAllogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the 'Endothelial Activation and Stress Index' (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria.
000147216 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147216 542__ $$2Crossref$$i2019-09-26$$uhttp://www.springer.com/tdm
000147216 542__ $$2Crossref$$i2019-09-26$$uhttp://www.springer.com/tdm
000147216 588__ $$aDataset connected to CrossRef, PubMed,
000147216 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000147216 7001_ $$0P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aTerzer, Tobias$$b2$$udkfz
000147216 7001_ $$aJodele, Sonata$$b3
000147216 7001_ $$00000-0002-4001-9203$$aDandoy, Christopher E$$b4
000147216 7001_ $$00000-0002-9343-4099$$aStorb, Rainer$$b5
000147216 7001_ $$00000-0003-3116-473X$$aKordelas, Lambros$$b6
000147216 7001_ $$aBeelen, Dietrich$$b7
000147216 7001_ $$aGooley, Ted$$b8
000147216 7001_ $$aSandmaier, Brenda M$$b9
000147216 7001_ $$aSorror, Mohamed$$b10
000147216 7001_ $$aZeisbrich, Markus$$b11
000147216 7001_ $$aRadujkovic, Aleksandar$$b12
000147216 7001_ $$aDreger, Peter$$b13
000147216 7001_ $$aPenack, Olaf$$b14
000147216 77318 $$2Crossref$$3journal-article$$a10.1038/s41409-019-0703-1$$bSpringer Science and Business Media LLC$$d2019-09-26$$n3$$p553-561$$tBone Marrow Transplantation$$v55$$x0268-3369$$y2019
000147216 773__ $$0PERI:(DE-600)2004030-1$$a10.1038/s41409-019-0703-1$$n3$$p553-561$$tBone marrow transplantation$$v55$$x0268-3369$$y2019
000147216 909CO $$ooai:inrepo02.dkfz.de:147216$$pVDB
000147216 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000147216 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000147216 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147216 9141_ $$y2020
000147216 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147216 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147216 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBONE MARROW TRANSPL : 2014
000147216 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147216 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000147216 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147216 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147216 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147216 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147216 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000147216 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147216 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147216 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000147216 980__ $$ajournal
000147216 980__ $$aVDB
000147216 980__ $$aI:(DE-He78)C060-20160331
000147216 980__ $$aUNRESTRICTED
000147216 999C5 $$1ML Sorror$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2006.09.7865$$p4246 -$$tJ Clin Oncol$$uSorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–54.$$v25$$y2007
000147216 999C5 $$1A Gratwohl$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(98)03030-X$$p1087 -$$tLancet$$uGratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–92.$$v352$$y1998
000147216 999C5 $$1A Gratwohl$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.24531$$p4715 -$$tCancer$$uGratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26.$$v115$$y2009
000147216 999C5 $$1P Armand$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2012-03-418202$$p905 -$$tBlood$$uArmand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905–13.$$v120$$y2012
000147216 999C5 $$1M Elsawy$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2016.141$$p1283 -$$tBone Marrow Transplant$$uElsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51:1283–1300.$$v51$$y2016
000147216 999C5 $$1VT Ho$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.bbmt.2005.06.001$$p571 -$$tBiol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant$$uHo VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2005;11:571–5.$$v11$$y2005
000147216 999C5 $$1K Riesner$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2016-08-736314$$p2021 -$$tBlood$$uRiesner K, Shi Y, Jacobi A, Krater M, Kalupa M, McGearey A, et al. Initiation of acute graft-versus-host disease by angiogenesis. Blood. 2017;129:2021–32.$$v129$$y2017
000147216 999C5 $$1T Ruutu$$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.10699$$p95 -$$tHaematologica$$uRuutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100.$$v92$$y2007
000147216 999C5 $$1SA Wall$$2Crossref$$9-- missing cx lookup --$$a10.1182/bloodadvances.2018020321$$p2619 -$$tBlood Adv$$uWall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2:2619–28.$$v2$$y2018
000147216 999C5 $$1M Zeisbrich$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2017.119$$p1399 -$$tBone marrow Transplant$$uZeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone marrow Transplant. 2017;52:1399–405.$$v52$$y2017
000147216 999C5 $$1S Paczesny$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2018-02-791509$$p2193 -$$tBlood$$uPaczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018;131:2193–204.$$v131$$y2018
000147216 999C5 $$1SJ Rotz$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMc1700185$$p1189 -$$tN Engl J Med$$uRotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link between GVHD and microangiopathy. N Engl J Med. 2017;376:1189–90.$$v376$$y2017
000147216 999C5 $$1MT Vander Lugt$$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1213299$$p529 -$$tN Engl J Med$$uVander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369:529–39.$$v369$$y2013
000147216 999C5 $$1S Jodele$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2015-08-663435$$p989 -$$tBlood$$uJodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989–96.$$v127$$y2016
000147216 999C5 $$1T Luft$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2011-02-334821$$p1685 -$$tBlood$$uLuft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92.$$v118$$y2011
000147216 999C5 $$1SP Rachakonda$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2013.54.4056$$p3421 -$$tJ Clin Oncol$$uRachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A, et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol. 2014;32:3421–7.$$v32$$y2014
000147216 999C5 $$1SP Rachakonda$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2017.76.4662$$p789 -$$tJ Clin Oncol$$uRachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A, et al. Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation. J Clin Oncol. 2018;36:789–800.$$v36$$y2018
000147216 999C5 $$1T Luft$$2Crossref$$9-- missing cx lookup --$$a10.1016/S2352-3026(17)30108-4$$pe414 -$$tLancet Haematol$$uLuft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017;4:e414.$$v4$$y2017
000147216 999C5 $$1TA Gerds$$2Crossref$$9-- missing cx lookup --$$a10.1002/bimj.200610301$$p1029 -$$tBiometrical J$$uGerds TA, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biometrical J. 2006;48:1029–40.$$v48$$y2006
000147216 999C5 $$1S Dietrich$$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.2013.090209$$p541 -$$tHaematologica$$uDietrich S, Okun JG, Schmidt K, Falk CS, Wagner AH, Karamustafa S, et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. Haematologica. 2014;99:541–7.$$v99$$y2014
000147216 999C5 $$1W Hanf$$2Crossref$$9-- missing cx lookup --$$a10.1155/2014/549315$$p549315 -$$tJ Immunol Res$$uHanf W, Bonder CS, Coates PT. Transplant glomerulopathy: the interaction of HLA antibodies and endothelium. J Immunol Res. 2014;2014:549315.$$v2014$$y2014
000147216 999C5 $$1J Chopra$$2Crossref$$uChopra J, Joist JH, Webster RO. Loss of 51chromium, lactate dehydrogenase, and 111indium as indicators of endothelial cell injury. Lab Invest. 1987;57:578–84.$$y1987
000147216 999C5 $$1P Coppo$$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0010208$$pe10208 -$$tPLoS ONE$$uCoppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5:e10208.$$v5$$y2010
000147216 999C5 $$1F Ayuk$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00277-015-2452-6$$p1727 -$$tAnn Hematol$$uAyuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, et al. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ann Hematol. 2015;94:1727–32.$$v94$$y2015
000147216 999C5 $$1Y Wei$$2Crossref$$9-- missing cx lookup --$$a10.1378/chest.14-1246$$p607 -$$tChest$$uWei Y, Wang Z, Su L, Chen F, Tejera P, Bajwa EK, et al. Platelet count mediates the contribution of a genetic variant in LRRC16A to ARDS risk. Chest. 2015;147:607–17.$$v147$$y2015
000147216 999C5 $$1M Zeisbrich$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2017.119$$p1399 -$$tBone Marrow Transplantation$$uZeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52:1399–1405.$$v52$$y2017
000147216 999C5 $$1TC Allen$$2Crossref$$9-- missing cx lookup --$$a10.5858/arpa.2013-0182-RA$$p266 -$$tArch Pathol Lab Med$$uAllen TC, Kurdowska A. Interleukin 8 and acute lung injury. Arch Pathol Lab Med. 2014;138:266–9.$$v138$$y2014
000147216 999C5 $$1C Pieper$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.brainres.2013.05.047$$p1 -$$tBrain Res$$uPieper C, Pieloch P, Galla HJ. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res. 2013;1524:1–11.$$v1524$$y2013
000147216 999C5 $$1R Cao$$2Crossref$$9-- missing cx lookup --$$a10.1096/fasebj.13.15.2195$$p2195 -$$tFASEB J$$uCao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999;13:2195–202.$$v13$$y1999
000147216 999C5 $$1SL Doyle$$2Crossref$$9-- missing cx lookup --$$a10.1126/scitranslmed.3007616$$p230ra44 -$$tSci Transl Med$$uDoyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, et al. IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration. Sci Transl Med. 2014;6:230ra44.$$v6$$y2014
000147216 999C5 $$1MC Durpes$$2Crossref$$9-- missing cx lookup --$$a10.1093/cvr/cvv107$$p303 -$$tCardiovasc Res$$uDurpes MC, Morin C, Paquin-Veillet J, Beland R, Pare M, Guimond MO, et al. PKC-beta activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. Cardiovasc Res. 2015;106:303–13.$$v106$$y2015
000147216 999C5 $$1JM Li$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jvs.2007.12.005$$p1048 -$$tJ Vasc Surg$$uLi JM, Eslami MH, Rohrer MJ, Dargon P, Joris I, Hendricks G, et al. Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model. J Vasc Surg. 2008;47:1048–57.$$v47$$y2008
000147216 999C5 $$1LA Bach$$2Crossref$$9-- missing cx lookup --$$a10.1530/JME-14-0215$$pR1 -$$tJ Mol Endocrinol$$uBach LA. Endothelial cells and the IGF system. J Mol Endocrinol. 2015;54:R1–13.$$v54$$y2015
000147216 999C5 $$1S Weischendorff$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2017.43$$p863 -$$tBone Marrow Transplant$$uWeischendorff S, Kielsen K, Sengelov H, Jordan K, Nielsen CH, Pedersen AE, et al. Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:863–9.$$v52$$y2017